

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

35-19898-01

Docket or Reference number

Amendment No. 03

City of Faith Medical and Research
Center
8131 S. Lewis
P.O. Box 36000
Tulsa, Oklahoma 74136

In accordance with letter dated July 28, 1982, License Number 35-19898-01
is amended as follows:

TO ADD:

- | | | |
|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| H. Iodine 131 | H. Iodide | H. 500 millicuries |
| I. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35 | I. Any radio-pharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35 | I. As necessary for uses authorized in Subitem 9.I. |
9. Authorized use
- H. For treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.
- I. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

35-19098-01

Docket or Reference number

Amendment No. 03

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Gilbert Maulsby, M.D.

Groups I, II, III, and VI
Americium 241 Anatomical Marker
Xenon 133
Depleted uranium for shielding

Patrick D. Lester, M.D.

Groups I, II and III
Xenon 133

Kenneth K. Wheatley, Jr.,
M.D.

Groups I, II, and III
Xenon 133

Charles R. Gosnell, M.D.

Groups I, II, III and V
Iodine 131 as iodide for treatment of
hyperthyroidism, cardiac dysfunction and
thyroid carcinoma

Phillip W. Jones, M.D.

Group VI

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated November 3, 1981, with Model ALARA Program; and letters dated January 11, 1982, May 21, 1982, and July 28, 1982. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Conditions 19. and 20. are added:

19. Patients containing Cobalt 60, Cesium 137 or Iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for five (5) years from the time the implants are removed.
20. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

For the U.S. Nuclear Regulatory Commission

Date

AUG 18 1982

By

Original signed by

F. A. B. 1982

Material Licensing Branch

Division of Fuel Cycle and
Material Safety
Washington, D.C. 20555

Fib
8/11/82

F. A. B. 1982

2